FDA Clears Waters' At-Home HPV Self-Collection Kit, Expanding Cervical Cancer Screening Access
WAT is trading near its 52-week low of $275.05 (10% above the low).
Summary
Waters Corporation has received FDA approval for its Onclarity HPV Self-Collection Kit and the BD Onclarity HPV Assay for at-home use. This significant regulatory milestone allows for expanded access to cervical cancer screening, a critical step in preventing the disease. The approval is particularly notable as the kit and assay are manufactured by Becton, Dickinson and Co., aligning with Waters' recent $16.8 billion acquisition of BD's Biosciences & Diagnostic Solutions, as noted in the company's last 10-K. This approval validates a key part of that strategic acquisition and opens up a new market opportunity for Waters, with the kit expected to be available by prescription and covered by major insurance providers.
At the time of this announcement, WAT was trading at $302.70 on NYSE in the Life Sciences sector, with a market capitalization of approximately $30.2B. The 52-week trading range was $275.05 to $414.15. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Dow Jones Newswires.